Page last updated: 2024-12-08

cyc 682

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sapacitabine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sapacitabine : A nucleoside analogue resulting from the formal condensation of the carboxy group of hexadecanoic acid with the amino group of CNDAC. It is the prodrug of CNDAC and is currently in clinical development for the treatment of acute myeloid leukemia (AML). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID153970
CHEMBL ID2105681
CHEBI ID145429
SCHEMBL ID711854
MeSH IDM0500495

Synonyms (44)

Synonym
cyc-682
cs-682
sapacitabine
cs 682
hexadecanamide, n-(1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl)-
n-(1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl)hexadecanamide
n-[1-[(2r,3s,4s,5r)-3-cyano-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide
cyc682
1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-4-(hexadecanoylamino)pyrimidin-2(1h)-one
CHEBI:145429
cs682
n-[1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidine-4-yl]hexadecanamide
cyc 682
sapacitabinum
pcndac
sapacitabina
151823-14-2
unii-w335p73c3l
w335p73c3l ,
2'-c-cyano-2'-deoxy-1-arabinofuranosyl-n(4)-palmitoylcytosine
sapacitabine [usan:inn]
sapacitabine (usan/inn)
D09722
CHEMBL2105681
SCHEMBL711854
sapacitabine [usan]
sapacitabine [inn]
hexadecanamide, n-(1-(2-cyano-2-deoxy-.beta.-d-arabinofuranosyl)-1,2-dihydro-2-oxo-4- pyrimidinyl)-
sapacitabine [who-dd]
n-(1-(2-cyano-2-deoxy-.beta.-d-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidin-4- yl)hexadecanamide
sapacitabine [mart.]
LBGFKUUHOPIEMA-PEARBKPGSA-N
DTXSID90164887
sapacitabine (cyc682)
n-(1-((2r,3s,4s,5r)-3-cyano-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)palmitamide
EX-A1617
DB06365
CS-0006340
HY-16445
Q7420893
MS-29120
nsc791785
nsc-791785
AC-36130

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Sapacitabine is an orally bioavailable nucleoside analog prodrug that is in clinical trials for hematologic malignancies and solid tumors."( Sapacitabine for cancer.
Kantarjian, H; Liu, X; Plunkett, W, 2012
)
0.38
"Sapacitabine is an orally bioavailable prodrug of the nucleoside analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)."( Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Liu, XJ; Nowak, B; Plunkett, W; Wang, YQ, 2012
)
0.38
" Its oral bioavailability and tolerable toxicity profile allow the drug to be used in an outpatient setting, especially in elderly unfit patients."( The efficacy of sapacitabine in treating patients with acute myeloid leukemia.
Czemerska, M; Robak, T; Wierzbowska, A, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" To confirm the safety and tolerability of dosing schedules, after 20 patients had been treated in a group we enrolled an expanded cohort of 20-25 patients to that group if at least four patients had achieved complete remission or complete remission with incomplete blood count recovery, and if the 30 day death rate was 20% or less."( Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Arellano, M; Chiao, J; Claxton, D; Coutre, S; Faderl, S; Garcia-Manero, G; Goldberg, SL; Jabbour, E; Kantarjian, H; Luger, S; Maness, L; Plunkett, W; Schiller, G; Seiter, K; Stock, W; Strickland, SA; Venugopal, P; Wetzler, M, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
DNA synthesis inhibitorAny substance that inhibits the synthesis of DNA.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (6.67)18.2507
2000's8 (26.67)29.6817
2010's20 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.56 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (16.67%)5.53%
Reviews7 (23.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]